# Aria CV

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aria-cv

- Industry: Medical Devices & Equipment
- Headquarters: St. Paul, US
- Website: www.ariacv.com
- Total disclosed funding: $37M
- Latest round: Series B (Feb 25, 2020)
- Investors on record: 7

## About

Aria CV, Inc. is a medical device company focused on developing innovative solutions for treating pulmonary hypertension through its investigational device, designed to enhance patient outcomes without reliance on electronic systems.Founded in 2010 and headquartered in St. Paul, US, Aria CV, Inc. specializes in creating advanced medical devices for pulmonary hypertension. The company was established by Karl Vollmers, who has a history of entrepreneurial ventures. As of February 2020, Aria CV raised USD 31.00 mn in SERIES B funding, led by Xeraya Capital, with participation from BioStar Capital, Catalyst Health Ventures, Cedar Point Capital, Frontcourt Ventures, and Longview Ventures. This round brought the total amount raised to USD 31.00 mn through five deals, the most recent occurring on 2020-02-25.Aria CV specializes in the development of an innovative medical device aimed at treating pulmonary hypertension. The core product, currently investigational, consists of a reservoir, a balloon, a narrow conduit for gas movement, and a nitinol anchor for balloon stabilization. It operates entirely on the heart's natural motion, eliminating the need for batteries, pumps, or electronic systems. The company focuses on clinical investigations within the United States, targeting hospitals and specialized medical centers as potential clients, with patients requiring advanced treatment options as end-users.Aria CV's revenue generation is closely tied to its investigational device addressing a critical healthcare need. Revenue typically arises from partnerships with clinical institutions and research centers conducting trials, possibly resulting in royalties or fees based on usage outcomes. The revenue model is centered around B2B relationships, facilitating the delivery of its flagship product to healthcare providers in exchange for compensation as per clinical trial agreements, which vary based on trial scope and scale, laying groundwork for future commercialization efforts.In February 2020, Aria CV, Inc. secured USD 31.00 mn in SERIES B funding, led by Xeraya Capital, to support the development of its investigational device and expand its market presence. The company plans to introduce new products targeting the pulmonary hypertension market while exploring expansion into additional geographical regions beyond the US. Details regarding specific new products or release dates have yet to be announced, but the recent funding will underpin these strategic initiatives.

## Funding rounds

- Series B, Feb 25, 2020, $31M — BioStar Capital, Catalyst Health Ventures, Cedar Point Capital, Xeraya Capital, Frontcourt Ventures, Longview Ventures
- Series A, Jul 24, 2015 — BioStar Capital, Catalyst Health Ventures, Broadview Ventures, Cedar Point Capital
- Series A, Dec 19, 2014, $6.3M — Catalyst Health Ventures, Broadview Ventures, Cedar Point Capital

## Investors

- Catalyst Health Ventures (https://capitalatlas.ai/funds/catalyst-health-ventures) — Series A, Series B
- Broadview Ventures (https://capitalatlas.ai/funds/broadview-ventures) — Series A
- Cedar Point Capital — Series A, Series B
- BioStar Capital (https://capitalatlas.ai/funds/biostar-capital) — Series A, Series B
- Xeraya Capital (https://capitalatlas.ai/funds/xeraya-capital) — Series B
- Frontcourt Ventures (https://capitalatlas.ai/funds/frontcourt-ventures) — Series B
- Longview Ventures — Series B